Literature DB >> 14744174

Gabapentin reduces cocaine use among addicts from a community clinic sample.

Wilfrid Noel Raby1, Siobhan Coomaraswamy.   

Abstract

BACKGROUND: Individuals with chronic psychiatric conditions display a high rate of cocaine use. Gabapentin was hypothesized to reduce cocaine use by restoring inhibitory GABAergic feedback on ascending dopaminergic projections to nucleus accumbens neurons.
METHOD: Nine participants with DSM-IV cocaine dependence were selected from patients attending a large community psychiatric clinic. During a 24-week open-label trial of gabapentin (800-2400 mg/day), qualitative urine drug screens were collected from the participants up to 3 times per week. Data were collected from September 1999 to May 2001.
RESULTS: With gabapentin, the mean +/- SD number of cocaine-positive urine screens decreased from 53.11 +/- 13.23 to 35.22 +/- 14.84 (t = 3.58, N = 9, p <.01). The number of weeks of abstinence from cocaine increased from 2.1 +/- 1.5 to 8.0 +/- 5.5 (t = 3.21, N = 9, p <.01).
CONCLUSION: Gabapentin appeared to be a safe and efficacious medication to reduce cocaine usage in a community sample of psychiatric patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744174     DOI: 10.4088/jcp.v65n0114

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

Review 1.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

3.  Diverse effects of GABA-mimetic drugs on cocaine-evoked self-administration and discriminative stimulus effects in rats.

Authors:  Małgorzata Filip; Małgorzata Frankowska; Magdalena Zaniewska; Anna Gołda; Edmund Przegaliński; Jerzy Vetulani
Journal:  Psychopharmacology (Berl)       Date:  2007-01-26       Impact factor: 4.530

Review 4.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 5.  Glutamatergic medications for the treatment of drug and behavioral addictions.

Authors:  M Foster Olive; Richard M Cleva; Peter W Kalivas; Robert J Malcolm
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

6.  Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats.

Authors:  Xiao-Qing Peng; Xia Li; Jie Li; P Veeraraghavan Ramachandran; Pravin D Gagare; Debarshi Pratihar; Charles R Ashby; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drug Alcohol Depend       Date:  2007-12-11       Impact factor: 4.492

Review 7.  Agents in development for the management of cocaine abuse.

Authors:  David A Gorelick; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

Review 9.  Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.

Authors:  Zheng-Xiong Xi; Eliot L Gardner
Journal:  Curr Drug Abuse Rev       Date:  2008-11

Review 10.  Gabapentin for the treatment of alcohol use disorder.

Authors:  Barbara J Mason; Susan Quello; Farhad Shadan
Journal:  Expert Opin Investig Drugs       Date:  2017-12-23       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.